Stock ARQT ARCUTIS BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Arcutis Biotherapeutics, Inc.

Equities

ARQT

US03969K1088

Market Closed - Nasdaq
Other stock markets
 04:00:02 2024-05-31 pm EDT 		5-day change 1st Jan Change
8.365 USD -3.41% Intraday chart for Arcutis Biotherapeutics, Inc. -8.68% +158.98%
May. 28 Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion MT
May. 15 Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion
Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday
Sector Update: Health Care
Mizuho Securities Adjusts Arcutis Biotherapeutics Price Target to $18 From $17, Maintains Buy Rating
Arcutis Biotherapeutics Q1 Loss Narrows as Revenue Surges; Shares Soar Premarket
Arcutis Biotherapeutics Q1 Loss Narrows, Revenue Increases; Shares Jump
Transcript : Arcutis Biotherapeutics, Inc., Q1 2024 Earnings Call, May 14, 2024
Arcutis Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Earnings Flash (ARQT) ARCUTIS BIOTHERAPEUTICS Posts Q1 Revenue $49.6M
Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology
Arcutis Biotherapeutics, Inc. Announces Journal of Clinical and Aesthetic Dermatology Publishes the Outcomes of a Comprehensive Evaluation by an Expert Dermatology
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
Arcutis Appoints David Topper as Chief Financial Officer
Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARQT Stock
  4. News Arcutis Biotherapeutics, Inc.
  5. Other languages